Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.46 |
| ▸ | ITK | Q08881 | 17/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656413 | 0.83 | NTRK1 (0.46) | NTRK1ITKCCNB2CCNE2CDK1 | |
| SCHEMBL14460641 | 0.83 | ITK (0.67) | NTRK1ITKCDK2 | |
| SCHEMBL14460463 | 0.81 | ITK (0.69) | NTRK1ITKCDK2 | |
| SCHEMBL5661570 | 0.80 | ITK (0.46) | NTRK1ITK | |
| SCHEMBL31242898 | 0.70 | OGA (0.42) | ITKCCNB2CCNE2CDK1CDK4 | |
| SCHEMBL5658029 | 0.70 | ITK (0.48) | NTRK1ITKCCNB2CCNE2CDK1 | |
| SCHEMBL5657635 | 0.69 | ITK (0.45) | NTRK1ITKCCNB2CCNE2CDK1 | |
| SCHEMBL25680801 | 0.69 | MAPT (0.64) | — | |
| SCHEMBL31242853 | 0.69 | KDR (0.38) | ITKCCNB2CCNE2CDK1CDK4 | |
| SCHEMBL14460653 | 0.68 | ITK (0.82) | ITKCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241781-B2 | 2-(pyridinylamino)thiazolylthio(optional methyl)-benzamides or -benzenealkanamides; may also contain antiinflammatory agents, antiproliferative agents, anticancer agents or anticytotoxic agents. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1671969-A2 | Thiazolyl inhibitors of tec family tyrosine kinases | Bristol-Myers Squibb Company (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7037926-B2 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1347971-B1 | THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20060030598-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JOEL C | 2006-02-09 | — | — | US | disclosed |
| US-6958336-B2 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| US-20040110752-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JOEL C (US) | 2004-06-10 | — | — | US | disclosed |
| US-20040077695-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JO I C (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040067990-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JOEL C (US) | 2004-04-08 | — | — | US | disclosed |
| US-20040067989-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BARRISH JOEL C (US) | 2004-04-08 | — | — | US | disclosed |
| US-6706717-B2 | ANTICANCER AGENTS; IMMUNOLOGY DISEASES; ANTIALLERGENS; ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-16 | — | — | US | disclosed |
| EP-1347971-A1 | THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES | Bristol-Myers Squibb Company (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030069238-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | disclosed |
| WO-2002050071-A1 | THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077695-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | NTRK1 625/4885ITK 10/4885CCNB2 3704/4885 |
| US-20040067990-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | NTRK1 625/4885ITK 10/4885CCNB2 3704/4885 |
| US-20040067989-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | NTRK1 625/4885ITK 10/4885CCNB2 3704/4885 |
| US-20030069238-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | NTRK1 625/4885ITK 10/4885CCNB2 3704/4885 |
| US-20060030598-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | NTRK1 625/4885ITK 10/4885CCNB2 3704/4885 |
| US-20040110752-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | NTRK1 625/4885ITK 10/4885CCNB2 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.